不同免疫球蛋白制剂中的蜱传脑炎病毒中和抗体
Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations.
作者信息
Rabel Philip O, Planitzer Christina B, Farcet Maria R, Kreil Thomas R
机构信息
Global Pathogen Safety, Baxter BioScience, Vienna, Austria.
出版信息
Clin Vaccine Immunol. 2012 Apr;19(4):623-5. doi: 10.1128/CVI.05705-11. Epub 2012 Feb 29.
Abstract
Patients with primary immunodeficiency (PIDs) depend on the presence of a variety of antibody specificities in intravenous immunoglobulin (IVIG). Using the tick-borne encephalitis virus (TBEV), geographic variability in IVIG antibody content was shown. Care should therefore be exercised when treating PIDs in a given geography, as only locally sourced plasma contains the antibody specificities against the circulating pathogens in the given locality.
摘要
原发性免疫缺陷（PID）患者依赖静脉注射免疫球蛋白（IVIG）中多种抗体特异性的存在。利用蜱传脑炎病毒（TBEV），已显示出IVIG抗体含量存在地理差异。因此，在特定地区治疗PID时应谨慎，因为只有当地来源的血浆才含有针对该地区循环病原体的抗体特异性。
相似文献
1
Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations.
Clin Vaccine Immunol. 2012 Apr;19(4):623-5. doi: 10.1128/CVI.05705-11. Epub 2012 Feb 29.
2
Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin.
Ticks Tick Borne Dis. 2017 Feb;8(2):253-258. doi: 10.1016/j.ttbdis.2016.11.007. Epub 2016 Nov 18.
3
Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.
Hum Vaccin Immunother. 2014;10(10):2819-33. doi: 10.4161/hv.29984.
4
Molecular Basis of a Protective/Neutralizing Monoclonal Antibody Targeting Envelope Proteins of both Tick-Borne Encephalitis Virus and Louping Ill Virus.
J Virol. 2019 Apr 3;93(8). doi: 10.1128/JVI.02132-18. Print 2019 Apr 15.
5
Stable and Highly Immunogenic MicroRNA-Targeted Single-Dose Live Attenuated Vaccine Candidate against Tick-Borne Encephalitis Constructed Using Genetic Backbone of Langat Virus.
mBio. 2019 Apr 23;10(2):e02904-18. doi: 10.1128/mBio.02904-18.
6
Pharmacokinetics of human tick-borne encephalitis virus antibody levels after injection with human tick-borne encephalitis immunoglobulin, solvent/detergent treated, FSME-BULIN S/D in healthy volunteers.
Scand J Infect Dis. 2001;33(11):843-7. doi: 10.1080/00365540110027358.
7
Evaluation of the European tick-borne encephalitis vaccine against Omsk hemorrhagic fever virus.
Microbiol Immunol. 2014 Feb;58(2):112-8. doi: 10.1111/1348-0421.12122.
8
Confirmed exposure to tick-borne encephalitis virus and probable human cases of tick-borne encephalitis in Central/Northern Anatolia, Turkey.
Zoonoses Public Health. 2011 May;58(3):220-7. doi: 10.1111/j.1863-2378.2010.01342.x.
9
[Donor immunization with an inactivated concentrated purified vaccine against tick-borne encephalitis to obtain immune blood preparations].
Vopr Virusol. 1984 Jan-Feb;29(1):56-9.
10
Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice.
BMC Infect Dis. 2016 Oct 7;16(1):544. doi: 10.1186/s12879-016-1884-5.
引用本文的文献
1
An autochthonous case of severe virus associated meningoencephalitis in France: Is there a place for polyvalent intravenous immunoglobulins?
IDCases. 2025 Mar 31;40:e02213. doi: 10.1016/j.idcr.2025.e02213. eCollection 2025.
2
Charting a course for global progress in PIDs by 2030 - proceedings from the IPOPI global multi-stakeholders' summit (September 2023).
Front Immunol. 2024 Jun 27;15:1430678. doi: 10.3389/fimmu.2024.1430678. eCollection 2024.
3
Severe Tick-Borne Encephalitis (TBE) in a Patient with X-Linked Agammaglobulinemia; Treatment with TBE Virus IgG Positive Plasma, Clinical Outcome and T Cell Responses.
J Clin Immunol. 2024 Apr 27;44(5):116. doi: 10.1007/s10875-024-01718-5.
4
Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance.
Front Immunol. 2023 Jan 9;13:987231. doi: 10.3389/fimmu.2022.987231. eCollection 2022.
5
Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease.
J Exp Med. 2021 May 3;218(5). doi: 10.1084/jem.20210236.
6
Characterization of antibodies in human immunoglobulin products from different regions worldwide.
Int J Infect Dis. 2021 Mar;104:610-616. doi: 10.1016/j.ijid.2021.01.034. Epub 2021 Jan 29.
7
Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention.
Open Forum Infect Dis. 2017 Sep 26;4(4):ofx204. doi: 10.1093/ofid/ofx204. eCollection 2017 Fall.
8
Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients.
Front Immunol. 2015 Feb 2;6:32. doi: 10.3389/fimmu.2015.00032. eCollection 2015.
9
Analysis of specific IgG titers against tick-borne encephalitis in patients with primary antibody deficiency under immunoglobulin substitution therapy: impact of plasma donor origin.
Front Immunol. 2015 Jan 5;5:675. doi: 10.3389/fimmu.2014.00675. eCollection 2014.
10
Characterization of antibody specificities associated with preeclampsia.
Hypertension. 2014 May;63(5):1086-93. doi: 10.1161/HYPERTENSIONAHA.113.02362. Epub 2014 Jan 20.
本文引用的文献
1
Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes.
Vaccine. 2012 Feb 1;30(6):1165-9. doi: 10.1016/j.vaccine.2011.12.013. Epub 2011 Dec 14.
2
Tick-borne encephalitis in Europe, 2007 to 2009.
Euro Surveill. 2011 Sep 29;16(39):19976. doi: 10.2807/ese.16.39.19976-en.
3
Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview.
Ticks Tick Borne Dis. 2011 Mar;2(1):2-15. doi: 10.1016/j.ttbdis.2010.10.007. Epub 2010 Dec 17.
4
Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations.
Transplantation. 2011 Aug 15;92(3):267-70. doi: 10.1097/TP.0b013e318224115e.
5
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans.
J Infect Dis. 2011 Jun 1;203(11):1556-64. doi: 10.1093/infdis/jir122.
6
Increasing West Nile virus antibody titres in central European plasma donors from 2006 to 2010.
Euro Surveill. 2011 Mar 10;16(10):19812. doi: 10.2807/ese.16.10.19812-en.
7
Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin.
J Med Virol. 2011 Feb;83(2):305-10. doi: 10.1002/jmv.21980.
8
Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus.
J Virol. 2011 Feb;85(4):1896-9. doi: 10.1128/JVI.02155-10. Epub 2010 Dec 1.
9
Tick borne encephalitis TBE--vaccination in non-endemic countries.
Travel Med Infect Dis. 2010 Jul;8(4):251-6. doi: 10.1016/j.tmaid.2010.05.007. Epub 2010 Jun 25.
10
Tick-borne encephalitis: pathogenesis and clinical implications.
Travel Med Infect Dis. 2010 Jul;8(4):223-32. doi: 10.1016/j.tmaid.2010.06.004. Epub 2010 Jul 21.
Zotero 插件